万维提示：
1、投稿方式：在线投稿。
2、官网网址：https://home.liebertpub.com/publications/thyroid/55
3、投稿网址：http://mc.manuscriptcentral.com/thyroid
4、官网邮箱：atajournal.thyroid@thyroid.org（编辑部）
5、官网电话：650-725-7830（主编）
6、期刊刊期：月刊，一个月出版一期。
2021年4月28日星期三
投稿须知
【官网信息】
Information For Authors
Preparation of Manuscript
Prepare text of manuscripts, figure legends, and tables in Microsoft Word, double spaced with standard font size 12. Avoid complex formatting such as columns. Use the “Tab” key at the start of a paragraph rather than the paragraph indent feature. The entire document should be paginated and all lines should be numbered throughout the entire manuscript. The order of elements in each manuscript should be:
Title page (with full manuscript title, all contributing authors’ full names, their highest-earned degrees, and complete affiliations and contact information including email addresses, a short running title, a denotation of the corresponding author, and a list of 3-6 keywords)
Abstract
Main text (do not embed figures or tables)
Conclusion (if required; include as a separate paragraph, not as part of the Discussion section)
Acknowledgments (if applicable)
Authorship confirmation statement (see below)
Author(s’) disclosure statement(s) (see below)
Funding statement (see below)
References
Figure legends
Tables
Supplemental files (if applicable. If the submission is accepted, Supplemental Information will NOT be published in the Just Accepted/LION platform, but instead will be published in the Online Now (epub) and final versions of the article. Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)
Abstract
For a Clinical or Basic Original Study, Reviews, and Case Studies, the abstract must be organized into the following four sections: Background, Methods, Results, and Conclusions. Start each section of the abstract in a new paragraph. The Background section should have one or two sentences regarding the background, followed by one or two sentences that state the objective of the study or the hypothesis that is tested in the study. The Conclusions should not restate the results but rather summarize the major findings and provide the reader with an indication of their importance and how they alter, support, extend, or refute widely held concepts. For Review and Scholarly Dialog articles, the abstract sections are as follows: Background, Summary, and Conclusions. For Patients with Remarkable Features or Rare Disorders, the abstract sections are as follows: Background, Patient Findings, Summary, and Conclusions.
Manuscript Text
Maximum word count for original studies should not exceed 3,000 words. For a Clinical or Basic Original Study, Reviews, and Case Studies, use the following sections: Introduction, Materials and Methods, Results, and Discussion. The Introduction should state the hypothesis in specific terms and provide a brief background that supports its rationale and importance. Review and Scholarly Dialog articles should be organized into the following sections: Introduction, Review, Summary, and Conclusions. For Patients with Remarkable Features or Rare Disorders there should be a brief introduction followed by a section titled Patient(s) (not “Case[s]”) followed by a discussion.
BRIEF REPORTS on novel mutations associated with inherited thyroid disorders
Reports on novel mutations associated with genetic thyroid disorders or recurring mutations that provide novel insights into the phenotypic spectrum should be prepared according to the following guidelines.
1. The index subject and family members should be evaluated with appropriate informed consent or/and assent.
2. Minimum information on the index subject should include: sex, age at the time of investigation, consanguinity, ethnic background and clinical presentation. The mode of transmission should be reported unless it is a de novo mutation.
3. Results from thyroid function testing are mandatory and abnormalities should be validated with a repeat measurement. When available, include relevant ancillary studies.
4. The minimum requirement is the study affected and unaffected first-degree relatives; if this is not possible, the reason for not studying family members should be mentioned. Include both clinical data and thyroid function tests.
5. Results from thyroid function tests should be as detailed as possible. Include analytical method, reference range, whether the sample was taken with or without treatment, and how long the treatment was stopped prior to the sampling. In case of dynamic testing (e.g. TRH test, T3 suppression test), indicate dose, duration, whether the individual was on any other treatment, and reference range for response.
6. Information regarding the identification of the mutation should include the source of DNA or RNA, the method of isolation and mutational analysis. Indicate cDNA and protein change and clarify the numbering of amino acids, for example in the presence of a signal peptide indicate if the numbering refers to the mature molecule or not.
For the description of mutations refer to Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Hum Mutat 1998;11:1-3. When the mutation is not present in the parents of the index subject, haplotype data could be added to support the presence or absence of allele sharing.
7. If the mutation is novel and not reported previously, provide evidence that it has not been reported in public databases (e.g. 1000 Genomes, dbSNP, Genome Variant Server) and that it is not a simple polymorphic variant. Provide in silico information on the expected effect of the mutation on protein function reporting scores from the SIFT and PolyPhen-2 algorithms. If possible, there should be data showing that the mutation has functional consequences. If in silico data is not supportive of the latter, in vitro studies should be included. If available, add information about protein structure and function, and interaction with other molecular partners.
Abbreviations and Nomenclature
Abbreviations and nomenclature should follow recommendations of the International Union of Biochemistry and Molecular Biology (IUBMB; Recommendations on Biochemical and Organic Nomenclature, Symbols and Terminology) at https://www.qmul.ac.uk/sbcs/iubmb/ The International System of Units (SI units) is recommended, but conventional units may also be used. In either case, it is desirable to include appropriate conversion factors to aid the reader. The list of abbreviations in the Journal of Endocrinology is generally acceptable in Thyroid.
Novel abbreviations should be kept to a minimum and must be defined when they first appear. Drug names should always be generic. Pedigrees should be drawn according to published standards (see Am J Hum Genet 56:745–752).(1) Human gene names and loci should be written in italicized capital letters and Arabic numerals (e.g., PAX8). Mouse genes should be written in italic using sentence case (e.g., Pax8). Protein names are not italicized (e.g., PAX8). For the description of human mutations, refer to Hum Mutat 11:1–3. (https://onlinelibrary.wiley.com/doi/epdf/10.1002/%28SICI%291098-1004%281998%2911%3A1%3C1%3A%3AAID-HUMU1%3E3.0.CO%3B2-O).(2) When a manuscript that contains novel sequences is accepted, the sequences must be deposited in the appropriate database (such as GenBank), an accession number obtained before the manuscript is sent to the publisher, and the accession number added in a footnote.
___________________________________________
1. Bennett RL, Steinhaus KA, Uhrich SB, O’Sullivan CK, Resta RG, Lochner-Doyle D, Markel DS, Vincent V, Hamanishi J. Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. Am J Hum Genet 1995;56:745–752.
2. Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Hum Mutat 1998;11:1–3.
References
References must be prepared in Word, double spaced, and numbered consecutively as they are cited in the text, in parentheses, e.g. (27). If you are using EndNoteTM, use the Output Styles for Thyroid. Include the reference section as part of the main text file, not as a separate file. References appearing for the first time in tables and figures must be numbered in sequence with those cited in the text where the table or figure is mentioned. Use journal abbreviations as provided by PubMed/Medline. List the first three authors, followed by et al., in the references. Do not bold volume numbers. If references to personal communications or unpublished data are used, they are not to be in the list of references. They should be referred to in the text in parentheses: (AB Jones, personal communication). Include among the references any articles that have been accepted but have not yet published; identify the name of publication and add "In Press." If the reference has been published online, provide the DOI number in place of the page range.
Written permission must be obtained from the author of any unpublished material cited from other laboratories, and it should accompany the manuscript.
Sample style for references:
Journal article:
Pearce SHS, Dayan C, Wraith DC, et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: A Phase I study. Thyroid. 2019;29:1003-1011.
Book:
Ellis PD. The essential Guide to Effect Sizes: Statistical Power, Meta-Analysis, and the Interpretation of Research Results. Cambridge University Press, Cambridge, United Kingdom, 2010.
Chapter in a book:
Figge JJ. Radiation-induced thyroid cancer. In: Wartofsky L, Van Nostrand D (eds.) Thyroid Cancer: A Comprehensive Guide to Clinical Management. 3rd ed. Springer-Verlag, New York, NY, 2016, pp 79-100.
Proceedings:
Lavilla S, González-López JJ, Larrosa MN, Bartolomé RM, Prat G. Prevalence of the quinolone-modifying enzyme aac(6´)-Ib-cr in extended-spectrum b-lactamase-producing enterobacterial isolates in Barcelona. Abstract no. P1523, presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, April 19–22, 2008.
Abstract:
Scacheri PC, Crabtree JS, Kennedy AL, Swain GP, Ward JM, Marx SJ, Spiegel AM, Collins FS. P2006. V804M RET mutation in MEN2A: first report. J Intern Med 2004;255:712 (abstract).
Website:
National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program database. Available at www.seer.cancer.gov Accessed May 26, 2020.
Figure Legends
Figure legends should be uploaded as a separate Word file and double spaced. In the legend, provide explanations for any abbreviations, arrows, etc. that appear in the figure. If the illustration is taken from a copyrighted publication, permission must be secured, appropriate credit must be given in the legend, and a corresponding reference must appear in the reference section.
Tables
All tables should be prepared in one single Word file. Provide a title for each table. Cite tables in sequence in the text. Explain abbreviations used in the body of the table in footnotes. The most important details of experimental conditions can be included in the table footnotes, and the reader can be referred to the Methods section for additional information. If the tables contain important information on methodology, there should be a brief reference in the Methods section directing the reader to the table containing the information. If the table is taken from a copyrighted publication, permission must be secured, appropriate credit must be given in the legend, and a corresponding reference must appear in the reference section.
Figures
Submission of high resolution .TIFF or .EPS figure files is strongly recommended.
Figures should not be embedded within the manuscript file.
Cite figures consecutively in text within parentheses.
A legend should be supplied for each figure and all legends numbered consecutively.
Images should not show the name of a patient or a manufacturer.
Do not include any illustrations as part of your text file.
Correspondence Address
Following the references, provide the name and complete affiliation and institutional email address of the person to whom correspondence should be sent.
Manuscript Revisions
To upload a revision of a manuscript, the submitting author should log in to their Author Center and click on “Revised Manuscripts in Draft.” All revised submissions will be required to meet all formatting conditions described herein. Submissions that do not satisfy these requirements will be un-submitted and returned to the submitting author for proper configuration.
The responses to reviewers and editors should be included in the cover letter, not in a separate file. It is important that the responses include statements regarding what changes were made in the revised manuscript. If the authors do not think that a change is required, it should be indicated. If the revision is submitted in Word®, use the Track Changes feature in the Tools menu to show the changes; otherwise, highlight the changes.
Letters to the Editor
Thyroid® will consider Letters to the Editor that respond to a recently published article in Thyroid or highlight relevant observations related to thyroid disorders. They are not a format to present the authors’ unpublished work. Letters should not exceed 500 words of text and 5 references. Letters submitted for publication must be original and must not be submitted to any other publication simultaneously.
For questions regarding manuscript submissions, contact our Author Services Division.
Thyroid is the Official Journal of the American Thyroid Association (ATA) with the editorial office at the ATA Office, 6066 Leesburg Pike, Suite 550, Falls Church, VA; website: www.thyroid.org.
……
